Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology(2019)
摘要
NCT02034981.
更多查看译文
关键词
ROS1 fusion,c-MET amplification,c-MET-mutation,crizotinib,lung cancer,targeted therapy
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要